tenofovir alafenamide HBV
Selected indexed studies
- Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (Expert Rev Anti Infect Ther, 2018) [PMID:29338458]
- Tenofovir alafenamide fumarate. (Antivir Ther, 2022) [PMID:35499175]
- Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. (Lancet Gastroenterol Hepatol, 2025) [PMID:39914435]
_Worker-drafted node — pending editorial review._
Connections
tenofovir alafenamide HBV is a side effect of
Sources
- Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial. (2023) pubmed
- Tenofovir alafenamide fumarate. (2022) pubmed
- Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (2018) pubmed
- Chronic Hepatitis B Infection: A Review. (2018) pubmed
- Early antiviral treatment with tenofovir alafenamide to prevent serious clinical adverse events in adults with chronic hepatitis B and moderate or high viraemia (ATTENTION): interim results from a randomised controlled trial. (2025) pubmed
- 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. (2018) pubmed
- EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017) pubmed
- Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti-HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial. (2025) pubmed
- Role of tenofovir alafenamide (TAF) in the treatment and prophylaxis of HIV and HBV infections. (2018) pubmed
- Long-Term Treatment With Tenofovir Alafenamide for Chronic Hepatitis B Results in High Rates of Viral Suppression and Favorable Renal and Bone Safety. (2024) pubmed